About Adocia
Adocia is a publicly listed company based in Lyon (France) founded in 2005. Therapeutics for diabetes and obesity treatment are developed. Adocia has raised $26 million across 5 funding rounds from investors including Idinvest Partners, IPF Partners and CDC Enterprises. The company has 77 employees. Adocia offers products and services including BioChaperone® Lispro and Pipeline Products. Its focus areas include Life Sciences, Diabetes, Drugs and Obesity.
Company details
Adocia was founded in 2005 in Lyon, France, within the biotechnology sector. Therapeutics targeting diabetes and obesity are developed using a proprietary Biochaperone platform, which improves protein effectiveness, safety, and patient administration. The clinical pipeline features a PDGF-BB formulation for diabetic foot ulcers and various insulin options for diabetes management. Operations focus on advancing these protein-based treatments through research and development.
- Headquarters Lyon, France
- Employees 77
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website adocia.com
- Social LinkedIn
- Legal Name Adocia Sa
- Annual Revenue$1.74 M (USD)-84.17as on Dec 31, 2025
- Net Profit-$19.49 M (USD)-78as on Dec 31, 2025
- EBITDA-$20.7 M (USD)-81.44as on Dec 31, 2025
- Total Equity Funding$26M (USD)
in 5 rounds
- Latest Funding Round$11.73M (USD), Post-IPO
Dec 2025
- InvestorsIdinvest Partners
& 5 more
- Employee Count77
Products & Services of Adocia
Adocia offers a comprehensive portfolio of products and services, including BioChaperone® Lispro and Pipeline Products.
Advanced insulin product for effective diabetes treatment in clinical settings.
Develops formulations for metabolic hormones targeting diabetes and obesity.
Funding Insights of Adocia
Adocia has successfully raised a total of $26M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $11.73 million completed in December 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $26M
- Total Rounds 5
- Last Round Post-IPO — $11.73M
- First Round $12M
(Jan 2008)
- Investors Count 6
All 5 funding rounds of Adocia with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2025 | $11.73M | Post-IPO | – | Stifel | – |
| Feb 2025 | $10.17M | Post-IPO | – | – | – |
| Oct 2019 | $16.51M | Debt – Conventional | – | – | |
| Jan 2010 | $14M | Series B | – | CDC Enterprises | – |
| Jan 2008 | $12M | Series A | – | Bioam, Idinvest Partners | – |
6 investors in total: 6 institutional.
Investors in Adocia
Adocia has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Idinvest Partners, IPF Partners and CDC Enterprises.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Alternative financing is provided by IPF Partners for healthcare. | ipfpartners.com | Luxembourg, Luxembourg | ||
Equity investments are provided to low and middle market companies. | 1997 | idinvest.com | Paris, France | |
Smalt Capital is engaged in capital investment and renewable energy financing. | 2000 | smaltcapital.com | Marseille, France | |
B2B portal for client imports, product management, and user account handling. | 1988 | cdcentreprises.fr | Paris, France | |
Functions as an online platform for comparing insurance options. | 2000 | bioam.fr | Paris, France | |
| stifel.com |
Investor details for Adocia
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Adocia
27 people are tracked at Adocia (11 in leadership, 16 in team); the tracked headcount is 77.
| Name | Role | Group |
|---|---|---|
David Rigal | Director Drug Product Development | Leadership |
Olivier Soula | co-founder, Chief Executive Officer, Director of Research & Development at ADOCIA | Leadership |
Véronique JANET | Head of Regulatory Affairs | Leadership |
Sophie JARRIX | Executive Assistant to the CEO | Leadership |
Valérie Danaguezian | Chief Financial Officer | Leadership |
Nicolas Laurent | Director of Research Chemistry Department | Leadership |
You-Ping Chan | Scientific Director | Leadership |
Anne-Lise Gaffuri | Director Of Biology Department | Leadership |
Jeremy Benattar | Head Of Business Strategy | Leadership |
Emmanuel Dauty | Director Of Innovation | Leadership |
Claire Mégret | Head of Clinics & PK/PD | Leadership |
Jenny Erales | Researcher Scientist In Drug Product Development | Team |
Charles Fortier | Expert Researcher In Drug Product Development | Team |
Romain Noel | Research Scientist | Team |
Ouardane Jouannot | Expert Scientist | Team |
Lucie Jamgotchian | Analytical chemistry scientist | Team |
Florence Debernardi | Technicienne Sciences Analytiques R &D | Team |
Laurine Bachelard | Technicienne De Laboratoire R&d En Biologie Et Biochimie | Team |
Baptiste Plancq | Research Scientist | Team |
Martin Gaudier | Directeur Scientifique | Team |
7 more people are available in the full profile.
Complete people profiles for Adocia
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Adocia
Adocia is a publicly listed company on the EURONEXT with ticker symbol ADOC in France, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date20 Feb 2012
- Listed onEuronext: ADOC
- Listed entityAdocia SA
- Exchange sectorHealth technology
- ISINFR0011184241
- Share price2.07 EUR (+2.48% on the day) · 2026-10-14
- Market capitalisation41,103,706.00 EUR
- EPS (diluted, trailing year)-0.83 EUR
- Volume (last session)23,585
Financials of Adocia
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 1.5M EUR | -16.6M EUR | -17.6M EUR |
| 2024 | 9.3M EUR | -9.3M EUR | -9.7M EUR |
| 2023 | 2.1M EUR | -21.2M EUR | -17.1M EUR |
| 2022 | 11.4M EUR | -6.9M EUR | -18.2M EUR |
| 2021 | 1.4M EUR | -22.8M EUR | -23.0M EUR |
Detailed financial statements for Adocia
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Adocia
4 dated milestones of Adocia across 20 years, from founding to its latest funding, stage changes and deals.
- Founded Adocia is founded.
- Funding First funding round of $12.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $11.7M.
Web traffic of Adocia
The website of Adocia (adocia.com) receives about 2.2K visits a month and ranks #3,636,776 among all websites worldwide, #4,679 in Biotechnology and Pharmaceuticals.
- Monthly visits2.2K
▼ 57.2% vs previous month
- Unique visitors2K
per month
- Global rank#3,636,776
among all websites
- Category rank#4,679
Health · Biotechnology and Pharmaceuticals
- Bounce rate46%
- Pages per visit1.8
- Average visit42 sec
- DevicesDesktop 35% · Mobile 65%
Websites whose visitors overlap most with Adocia. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| molecularpartners.com | 83% | 12.3K | #2,658,648 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Adocia
Complete news archive for Adocia
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Adocia
Adocia was founded in 2005 and raised its 1st funding round 3 years after it was founded.
Adocia is headquartered in Lyon, France. It is registered at Lyon, Auvergne-rhone-alpes, France.
Adocia is a funded company, having raised a total of $26M across 5 funding rounds to date. The company's 1st funding round was a Series A of $12M, raised on Jan 2008.
Adocia has 77 employees.
Annual revenue of Adocia is $1.74M as on Dec 31, 2025.
Adocia was founded in 2005 in Lyon, France, within the biotechnology sector. Therapeutics targeting diabetes and obesity are developed using a proprietary Biochaperone platform, which improves protein effectiveness, safety, and patient administration. The clinical pipeline features a PDGF-BB formulation for diabetic foot ulcers and various insulin options for diabetes management. Operations focus on advancing these protein-based treatments through research and development.
Adocia offers BioChaperone® Lispro and Pipeline Products.
Yes, Adocia is publicly traded on EURONEXT under the ticker symbol ADOC.
Adocia has 6 investors. Key investors include Idinvest Partners, IPF Partners, CDC Enterprises, Bioam, and Smalt Capital.